QURE QURE
Company Profile ↓Company Overview
QURE (QURE) is a publicly traded company listed on with a market capitalization of $2.77B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.32.
Recent Developments
- Dec 2025 Revenue of $16.10M (-40.6% YoY); net profit $-198.97M.
- Trailing 12 Months Year-on-year growth — revenue -40.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.16% |
| 1 Year: | -40.64% |
Stock Price Performance
| 1 Year: | +221.28% |
| 6 Months: | +59.14% |
| 3 Months: | +109.07% |
| 1 Month: | +6.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 37.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.26M | 3.70M | 5.57M | 3.56M | 5.84M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 656.00K | 398.00K | 435.00K | 219.00K | 350.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.61M | 3.30M | 5.13M | 3.34M | 5.49M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.49M | 52.79M | 56.63M | 47.61M | 50.17M |
| Operating Income | -19.26M | -22.13M | -14.16M | -19.71M | -19.71M | -9.28M | -19.60M | -21.20M | -23.22M | -27.50M | -29.33M | -31.33M | -34.46M | -38.21M | -44.49M | -44.46M | 398.01M | -45.00M | -54.08M | -56.06M | -59.52M | -74.17M | -65.07M | -81.88M | -54.23M | -44.01M | -40.23M | - | -42.88M | -49.49M | -51.49M | -44.27M | -44.68M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.07M | -51.55M | -23.46M | -36.06M | -59.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.59M | 16.72M | 14.57M | 14.03M | 14.37M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.29M | -71.90M | -41.00M | -53.05M | -79.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 425.00K | 8.63M | -3.92M | 488.00K | 1.84M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -56.30M | -44.38M | - | -37.72M | -80.53M | -37.09M | -53.53M | -81.06M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.96 | -1.21 | -0.91 | 8.51 | -0.79 | -1.00 | -0.84 | -1.02 | -1.63 | -1.44 | -1.88 | -1.36 | -1.16 | -0.91 | -0.82 | -0.69 | -1.38 | - | -0.85 | -1.22 |
| R&D Expense | 16.71M | 19.22M | 16.60M | 16.99M | 16.87M | 20.10M | 17.06M | 18.49M | 20.54M | 20.54M | 24.15M | 23.55M | 26.01M | 28.40M | 36.30M | 32.66M | 32.75M | 36.43M | 45.00M | 46.19M | 48.07M | 60.81M | 46.04M | 65.40M | 40.69M | 33.66M | 30.59M | 36.14M | 35.38M | 34.37M | - | 29.18M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.14M | 10.58M | 25.10M | 13.11M | 11.28M | 7.28M | 37.51M | 524.00M | 106.48M | 15.84M | 27.12M | 16.10M |
| Cost of Revenue | - | - | - | - | - | - | - | - | 3.34M | 13.63M | 18.33M | 1.69M |
| Gross Profit | - | - | - | - | - | - | - | - | 103.14M | 2.21M | 8.79M | 14.41M |
| Operating Expenses | - | - | - | - | - | - | - | - | 247.39M | 284.70M | 190.97M | 202.24M |
| Operating Income | -53.68M | -71.15M | -71.95M | -71.34M | -88.23M | -121.14M | -125.43M | 310.62M | -144.25M | -282.49M | -182.18M | -187.83M |
| EBITDA | - | - | - | - | - | - | - | - | -108.02M | -253.10M | -160.75M | -116.59M |
| Interest Expense | - | - | - | - | - | - | - | - | 11.70M | 41.56M | 63.74M | 61.99M |
| Pretax Income | - | - | - | - | - | - | - | - | -128.26M | -306.56M | -237.13M | -193.34M |
| Tax Provision | - | - | - | - | - | - | - | - | -1.47M | 1.92M | 2.43M | 5.63M |
| Net Income | -49.78M | -82.08M | -73.37M | -79.26M | -83.30M | -124.20M | -125.02M | 329.59M | -126.79M | -308.48M | -239.56M | -198.97M |
| Diluted EPS | - | - | - | - | - | -3.11 | -2.81 | 7.04 | -2.71 | -6.47 | -4.92 | -3.46 |
| R&D Expense | 43.77M | 59.12M | 72.51M | 72.17M | 74.81M | 94.74M | 122.40M | 143.55M | 197.59M | 214.86M | 143.78M | 140.67M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 262.66M | 190.26M | 209.64M | 273.91M | 448.63M | 340.39M | - | 704.96M | 831.69M | 556.54M | 824.91M |
| Current Assets | - | - | - | - | - | - | - | - | - | 476.77M | 651.85M | 390.29M | 655.99M |
| Cash & Equivalents | 32.78M | 64.69M | 221.63M | 132.50M | 159.37M | 234.90M | 377.79M | 244.93M | - | 228.01M | 241.36M | 158.93M | 80.24M |
| Inventory | - | - | - | - | - | - | - | - | 0 | 6.92M | 12.02M | 0 | - |
| Receivables | - | - | - | - | - | - | - | - | - | 102.38M | 4.19M | 5.88M | 5.86M |
| Total Liabilities | - | - | 134.74M | 126.63M | 120.28M | 94.30M | 125.57M | 96.49M | - | 228.96M | 624.02M | 563.29M | 626.01M |
| Current Liabilities | - | - | 26.91M | 22.72M | 19.23M | 19.97M | 31.63M | 27.33M | - | 75.92M | 73.67M | 40.05M | 62.92M |
| Long Term Debt | - | - | 14.63M | 19.63M | 19.74M | 35.47M | 36.06M | 35.62M | - | 102.79M | 101.75M | 51.32M | 49.70M |
| Total Debt | - | - | - | - | - | - | - | - | - | 142.89M | 138.41M | 66.06M | 63.39M |
| Total Equity | 2.29M | 42.63M | 127.93M | 63.63M | 89.36M | 179.61M | 323.06M | 243.91M | - | 476.01M | 207.67M | -6.75M | 198.90M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 46.97M | 47.83M | 48.99M | 62.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | 7.47M | -72.19M | -64.27M | -76.04M | -98.68M | -134.83M | - | -145.06M | -145.93M | -182.73M | -177.96M |
| Investing Cash Flow | - | -8.02M | -17.17M | -5.58M | -4.25M | -6.65M | -9.48M | - | -182.73M | -205.69M | 162.97M | -321.62M |
| Financing Cash Flow | - | 160.69M | 2.44M | 90.07M | 157.96M | 248.82M | 7.44M | - | 1.45M | 362.72M | -59.49M | 415.40M |
| Capital Expenditure | -22.20M | -7.61M | -15.29M | -4.46M | -2.38M | -5.65M | -7.27M | - | -17.69M | -7.15M | -11.69M | -439.00K |
| Free Cash Flow | - | -139.00K | -87.48M | -68.73M | -78.42M | -104.33M | -142.10M | - | -162.75M | -153.08M | -194.42M | -178.40M |
| Net Change in Cash | - | - | - | - | - | - | - | - | -326.35M | 11.11M | -79.25M | -84.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 96.9% | 14.0% | 32.4% | 89.5% |
| Operating Margin % | -874.2% | -672.6% | -286.7% | -544.3% | -781.9% | -1,663.8% | -334.3% | 59.3% | -135.5% | -1,783.0% | -671.8% | -1,166.8% |
| Net Margin % | -810.6% | -776.0% | -292.3% | -604.7% | -738.2% | -1,705.8% | -333.3% | 62.9% | -119.1% | -1,947.1% | -883.4% | -1,236.0% |
| ROE % | -116.8% | -64.2% | -115.3% | -88.7% | -46.4% | -38.4% | -51.3% | - | -26.6% | -148.5% | 3,547.9% | -100.0% |
| ROCE % | - | -30.2% | -42.9% | -37.5% | -34.7% | -29.1% | -40.1% | - | -22.9% | -37.3% | -35.3% | -24.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QURE
QURE Stock Just Shot Up 8% - uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNY0tPbUFINEhwMU9PRUNMMEVMNUF5UmplQTdhWTUtSU1hVnRQUUhzaklpdU5xdkN5aW9tdWpVR2EySDctYm5WQnJTc0NlTVdiOE93bkkyUzBVbERSZWoxdlhwY1NXRUVLVEVGbUo2VTg3VnFqU0d5U0cwOEJ2dFhpeTJxUlJ5clpNVldhbG…
uniQure (QURE) Stock Still Looks Expensive Given Its Huntingtons Promise - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNeHNIMmxWZkRrWGhYV2kzaFBhdFliNmY5MlJLblR4RXNCdC16Nk42RmhGa1JQX3JvMF9kTlNDWTRlbGRJeWduRkx2SWpZd2QwUU0tQV9rYW5sa0pBQjJ3MW5LQzNBWEZTNHEteWViekJzU0ROeWpCYzFSOXRweXhNZFNLVEdUQlFPS2NPMD…
uniQure (QURE) Stock Rises On Cash Runway Despite Deepening Losses - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPWS1wUER2V0ltTGUwdzZfaXp4TWZzeV81Skl3VFNUSElHT0xwNmxLQ0psLWdHNVZBa0czV0Q0X1pGNU92X2NIRTBLMThDSVExSldBOF9TMW1qa2dZOXBWT21JU2JodzVxOWRFU3pLVDVLdzdZejdKd2lCNmVTeGRXbmNoMjdRTU44R1htTF…
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOVk91ekxIX2ZHU0RuTmNhVEtONlZQOTlsOGtsSkZXbUZmMlFGZ2drd1AzMmJJSVdYMG56WlZFTlBRTkJKZnNoRExsRUNjVHdGWDBNTkRLd04wbHAzMFpFSkx3bjBNR2ZxTjlTMzEtYWtnS0RORi0tZThvYnF5Wm5JMHpVdElmRlBvTlJmVk…
$QURE stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQekZ3UDZWdWxPZDFrRzBLcXFxZTZVb09aRGVVYkhGU1ZjZVRFdlJzSmVHZ2oybkctYV8zMFRwYjJzaTZDbjVrZzZLcDl0Q2Q3MXcwTlNlUUI1S0daaEFmbS1ES3FzOEVzWml1ZFh4aXRSbHdVakdIR3hPN05ZUFRuNTJOMUxKdXVJME0wbk…
5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX - rttnews.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQWVBva3B0VXM5eW1lM1FIN3RPMktVUC1LLVk1anBOZU9rSEsxY1ZjN3VpYjJzbVVJVGc5U0dsRmc3U0llQkxqVFQ4R2ItZ2RXbzY2MlBwV0RZajM2OG1uNzVVMng0R05CMVVGTWVVLWRoQ19mcWVma1VOMGE3OExqWmoySFp4a09GRG1UTU…
QURE — Frequently Asked Questions
What is the current share price of QURE?
As of 2026-08-05 17:25 PDT, QURE trades at $44.24 on NASDAQ/NYSE. Its 52-week range is $9.03 to $70.59.
What is the market capitalisation of QURE?
QURE has a market capitalisation of $2.77B on NASDAQ/NYSE.
What is the P/E ratio of QURE?
QURE trades at a trailing price-to-earnings (P/E) ratio of -12.79. Its price-to-book (P/B) ratio is 13.91.
What is the return on equity (ROE) of QURE?
QURE has a return on equity (ROE) of -100.04%. Its return on capital employed (ROCE) is -24.65%.
Is QURE a good stock to buy?
This page provides a data-driven analysis of QURE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.